IVDR Clinical Evidence Is Becoming a Living System: What Diagnostics Manufacturers Should Do Next
IVDR and global IVD evidence expectations are pushing diagnostics manufacturers toward living clinical evidence systems. Learn how to connect scientific validity, analytical performance, clinical performance, PMS, and change control.
By Melita Ball
IVDR has changed the evidence burden for diagnostics manufacturers. The practical shift is bigger than a new technical documentation checklist. Clinical evidence for IVDs is becoming a living system.
That matters because IVD evidence is not static. Scientific validity can evolve as medical knowledge changes. Analytical performance may be affected by reagent changes, instruments, specimen handling, software updates, supplier materials, or manufacturing drift. Clinical performance can be influenced by population, prevalence, clinical workflow, comparator methods, and real-world use.
A diagnostics manufacturer that treats evidence as a one-time submission package may be able to assemble a file. The harder question is whether the company can maintain that file as the product, claims, markets, data, and risks change.
The short answer
IVDR readiness depends on evidence continuity.
Manufacturers need a controlled way to define, generate, approve, monitor, update, and defend scientific validity, analytical performance, and clinical performance across the product lifecycle.
If evidence is scattered across literature folders, lab reports, spreadsheets, emails, supplier files, and old submission binders, the organization may not be able to explain whether the evidence still supports the product on the market today.
Why this matters now
Diagnostics manufacturers are facing pressure from multiple directions. IVDR has raised expectations for clinical evidence and performance evaluation. Notified Body review requires a more disciplined evidence story. Global regulatory convergence efforts are emphasizing updated definitions and principles for IVD clinical evidence. At the same time, IVD products are becoming more complex, especially where software, companion diagnostics, multiplex testing, decentralized testing, or AI-supported interpretation are involved.
The result is an operating problem, not only a regulatory writing problem.
Regulatory affairs may own the submission. Clinical or medical affairs may own literature and clinical performance. R&D may own analytical studies. Quality may own change control, suppliers, deviations, nonconformities, CAPA, and PMS. Manufacturing may own process performance. Commercial teams may influence claims and intended users.
IVDR evidence sits across all of those functions.
Where manufacturers get stuck
Scientific validity is not actively maintained
Scientific validity explains the association between an analyte, marker, measurand, or test output and the clinical condition or physiological state of interest. It is foundational to the product's intended purpose.
For many diagnostics teams, scientific validity starts as a literature exercise and then becomes a static appendix. That is risky. New clinical practice, updated guidelines, emerging variants, changing standard of care, or new comparator methods may affect whether the original rationale remains current.
A manufacturer needs ownership, review frequency, source control, and escalation criteria.
Analytical performance is disconnected from operational change
Analytical performance is often supported by structured studies, but the product does not freeze after those studies are complete. Suppliers change. Reagents change. Manufacturing processes change. Instruments are updated. Software is patched. Stability data matures. Complaints reveal edge cases.
Each change may or may not affect performance evidence. The quality system needs a way to decide that consistently.
If change control does not ask evidence impact questions, the performance evaluation file can quietly drift away from the device.
Clinical performance is treated as a submission milestone
Clinical performance evidence should support the device's ability to produce results associated with the target clinical condition or intended use. Under IVDR, that evidence needs to be planned, justified, documented, and maintained.
The problem is that many organizations still approach clinical performance as a premarket hurdle. Once the file is submitted, attention shifts to the next project.
That mindset creates risk. Post-market data, complaints, user feedback, literature, proficiency trends, and product changes may all affect the performance story.
Claims change faster than evidence
Diagnostics claims can evolve through commercial pressure, customer feedback, new populations, workflow expansion, software features, or global market strategy. Even small wording changes can matter.
If claims are not controlled across labeling, sales materials, technical documentation, risk management, and evidence files, the manufacturer may end up with unsupported or inconsistent statements.
A practical evidence readiness check
Choose one IVD product family and ask:
- Is the intended purpose current and consistent across all controlled documents?
- Is scientific validity documented, approved, and assigned to an owner?
- Are literature review methods and review intervals defined?
- Are analytical performance studies linked to design inputs, risk controls, acceptance criteria, and change records?
- Are clinical performance conclusions tied to the intended population, specimen type, workflow, and claims?
- Are evidence gaps tracked with owners and due dates?
- Does PMS feed the performance evaluation process?
- Does change control assess impact on scientific validity, analytical performance, clinical performance, labeling, and technical documentation?
- Can the team produce the evidence chain without manual reconstruction?
If the evidence story changes depending on which department answers, the system needs work.
What good looks like in practice
A mature IVD evidence system starts with regulatory strategy and intended purpose. It defines the evidence burden early. Scientific validity, analytical performance, and clinical performance are planned as connected evidence streams. Design controls, risk management, supplier controls, lab studies, clinical or performance data, labeling, PMS, and change control all feed the same controlled product story.
When a change occurs, the company can assess whether evidence is affected. When a complaint trend appears, the company can decide whether performance evaluation needs review. When a new market is added, the company can identify what evidence can be leveraged and what must be supplemented.
That is what living evidence looks like.
Key takeaways
- IVDR has made clinical and performance evidence a continuing operational responsibility.
- Scientific validity, analytical performance, and clinical performance should be connected to intended purpose, claims, risk, PMS, and change control.
- Evidence files should not be rebuilt manually before each review or submission.
- Diagnostics manufacturers need clear ownership and review triggers for evidence maintenance.
- A connected compliance platform helps IVD teams maintain evidence as the product and markets evolve.
How IntelaSolve helps
IntelaSolve supports diagnostics manufacturers across regulatory strategy, design controls, risk management, clinical and performance evidence, technical documentation, supplier quality, PMS, CAPA, and lifecycle change. By connecting evidence to the processes that generate and affect it, IntelaSolve helps IVD teams keep performance evaluation current, controlled, and ready for review.
Request early access to IntelaSolve or complete the Compliance Readiness Analysis to identify whether your IVD evidence system is ready for IVDR and global lifecycle expectations.